

Time: October 11, 7:30 p.m.—recess;
October 12, 8 a.m.—recess; October 13, 8
a.m.—adjournment.

Place: Hampshire Hotel, 1310 New
Hampshire Avenue, N.W., Washington, DC
20036.

Contact Person: Dr. Paul Sheehy, Scientific
Review Administrator, National Institutes of
Health, Federal Building, Room 9C-10,
Bethesda, MD 20892, (301) 496-9223.

Name of Committee: Neurological
Disorders Program Project Review A
Committee.

Date: October 25-27, 1995.

Time: October 25, 7:30 p.m.—recess;
October 26, 8:30 a.m.—recess; October 27,
8:30 a.m.—adjournment.

Place: Bethesda Holiday Inn, 8120
Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Dr. Katherine Woodbury,
Scientific Review Administrator, National
Institutes of Health, Federal Building, Room
9C-14, Bethesda, MD 20892, (301) 496-9223.

Name of Committee: Training Grant and
Career Development Review Committee.

Date: November 8-10, 1995.

Time: November 8, 9 a.m.—recess;
November 9, 8:30 a.m.—recess; November 10,
8:30 a.m.—adjournment.

Place: Hyatt Islandia, San Diego's Mission
Bay, 1441 Quivira Road, San Diego, CA
92109-7898.

Contact Person: Dr. Alfred Gordon,
Scientific Review Administrator, National
Institutes of Health, Federal Building, Room
9C-14, Bethesda, MD 20892, (301) 496-9223.

(Catalog of Federal Domestic Assistance
Program No. 93.853, Clinical Research
Related to Neurological Disorders; No.
93.854, Biological Basis Research in the
Neurosciences)

Dated: July 24, 1995.

Susan K. Feldman,

*Committee Management Officer, National
Institutes of Health.*

[FR Doc. 95-18531 Filed 7-27-95; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Closed Meetings

Pursuant to Section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following Division
of Research Grants Special Emphasis
Panel (SEP) meetings:

Purpose/Agenda: To review individual
grant applications.

Name of SEP: Microbiological and
Immunological Sciences.

Date: August 8, 1995.

Time: 4:00 p.m.

Place: NIH, Rockledge II, Room 4208,
Telephone Conference.

Contact Person: Dr. Anita Weinblatt,
Scientific Review Administrator, 6701
Rockledge Drive, Room 4208, Bethesda, MD
20892, (301) 435-1224.

Name of SEP: Chemistry and Related
Sciences.

Date: August 10, 1995.

Time: 2:30 p.m.

Place: NIH, Rockledge II, Room 4150,
Telephone Conference.

Contact Person: Dr. Marcia Litwack,
Scientific Review Administrator, 6701
Rockledge Drive, Room 4150, Bethesda, MD
20892, (301) 435-1719.

Name of SEP: Microbiological and
Immunological Sciences.

Date: August 14, 1995.

Time: 1:00 p.m.

Place: NIH, Rockledge II, Room 4200,
Telephone Conference.

Contact Person: Dr. Gilbert Meier,
Scientific Review Administrator, 6701
Rockledge Drive, Room 4200, Bethesda, MD
20892, (301) 435-1219.

Name of SEP: Chemistry and Related
Sciences.

Date: August 15, 1995.

Time: 10:00 a.m.

Place: NIH, Rockledge II, Room 4150,
Telephone Conference.

Contact Person: Dr. Marcia Litwack,
Scientific Review Administrator, 6701
Rockledge Drive, Room 4150, Bethesda, MD
20892, (301) 435-1719.

The meetings will be closed in
accordance with the provisions set forth in
secs. 552b(c)(4) and 552(c)(6), Title 5,
U.S.C. Applications and/or proposals
and the discussions could reveal
confidential trade secrets of commercial
property such as patentable material
and personal information concerning
individuals associated with the
applications and/or proposals, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.

This notice is being published less
than 15 days prior to the meeting due
to the urgent need to meet timing
limitations imposed by the grant review
cycle.

(Catalog of Federal Domestic Assistance
Program Nos. 93.306, 93.333, 93.337, 93.393-
93.396, 93.837-93.844, 93.846-93.878,
93.892, 93.893, National Institutes of Health,
HHS)

Dated: July 24, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-18537 Filed 7-27-95; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Mouse Monoclonal Antibodies Specific for Normal Primate Tissue, Malignant Human Cultured Cell Lines and Human Tumors

AGENCY: National Institutes of Health,
Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i) that the National Institutes
of Health (NIH), Department of Health

and Human Services, is contemplating
the grant of an exclusive world-wide
license to practice the inventions
embodied in U.S. Patent 5,242,813, U.S.
Patent Applications 08/051,133 and 08/
363,203 and corresponding foreign
patent applications entitled "Mouse
Monoclonal Antibodies Specific For
Normal Primate Tissue, Malignant
Human Cultured Cell Lines and Human
Tumors" to Pharmacia, S.P.A. of
Milano, Italy. The patent rights in these
inventions have been assigned to the
United States of America.

The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.

The present invention includes three
murine monoclonal antibodies (MAb),
B1, B3 and B5. These antibodies react
strongly with the Lewis Y blood group
antigen on many human solid tumors
but weakly with normal human tissues.
MAb B3 reacts strongly with 10% of
transitional cell carcinomas of the
bladder, 75% of adenocarcinomas of the
colon, 70% of adenocarcinomas of the
lung, 65% with adenocarcinomas of the
prostate, 40% of squamous cell
carcinomas of the lung and 25% of large
cell carcinomas. MAb B3 reacts
heterogeneously with 70% of breast
carcinomas. Several important
characteristics of this antibody make it
an ideal candidate for further
development: (1) Its strong and uniform
reactivity with many human solid
carcinomas; (2) its limited reactivity
with normal tissues; (3) its expression
on both human and monkey tissues will
allow for predictive preclinical
toxicology studies in monkeys.
Additionally, these antibodies, when
incorporated as the targeting element of
an immunotoxin, have been shown to
allow efficient entry of toxin agents into
cells. These antibodies should be useful
in the diagnosis and treatment of some
forms of cancer.

ADDRESSES: Requests for copies of the
patent applications, inquiries,
comments and other materials relating
to the contemplated licenses should be
directed to: Raphe Kantor, Ph.D.,
Technology Licensing Specialist, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852-3804. Telephone: (301)